NRx Gets Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI during Omicron Surge

 A Southwestern hospital has reported safety data collected under the Federal Right to Try law indicating that 16 of 19 patients (84%) with COVID-19 respiratory failure treated with ZYESAMI® by Dec 31, 2021 have survived the ICU.

-No Serious Adverse Events were reported

-Patients were treated during the Omicron Surge

-Patients were treated at first onset of respiratory failure after exhausting remdesivir and other approved therapies

-Data are being included provided by NRx to FDA in support of ongoing application to FDA for Emergency Use Authorization

https://finance.yahoo.com/news/nrx-receives-initial-report-patient-115100026.html